Additionally, IGF-1 levels, the primary mediator of many GH effects, show dose-dependent increases in response to combined CJC-1295 and Ipamorelin treatment in rodent models
Every vial is fitted with a bromobutyl rubber stopper and tamper-evident aluminium seal to help maintain product integrity throughout storage and laboratory handling
For the most up-to-date clinical criteria for other indications, please visit the Western Health Advantage website for PA and NF Criteria

Renal function should be checked if prolonged gastrointestinal symptoms occur, especially in those with existing kidney disease For injection site reactions: Rotate injection sites (abdomen, thigh, upper arm) to prevent localised irritation Allow the medication to reach room temperature before injecting Use proper injection technique as demonstrated by your healthcare provider Important safety considerations: Women using oral contraceptives should use non-oral or barrier methods for 4 weeks after starting tirzepatide and after each dose increase, as absorption may be affected [1] If you are taking insulin or sulphonylureas, your doctor may need to reduce these doses to prevent hypoglycaemia Report symptoms of gallbladder disease (severe right upper abdominal pain, jaundice) promptly Attend all scheduled follow-up appointments to monitor glycaemic control, weight, and overall tolerability Report any new, persistent, or worsening symptoms to your healthcare team promptly Do not discontinue Mounjaro without consulting your prescriber, as abrupt cessation may affect diabetes control Be aware of signs of pancreatitis (severe, persistent abdominal pain radiating to the back) and seek immediate medical attention if these occur Your healthcare provider can offer personalised advice based on your individual circumstances, comorbidities, and treatment goals
